

Hidekazu Sugiura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8593869/publications.pdf>

Version: 2024-02-01

32
papers

1,006
citations

566801

15
h-index

476904

29
g-index

32
all docs

32
docs citations

32
times ranked

1254
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative Stress Decreases Klotho Expression in a Mouse Kidney Cell Line. <i>Nephron Experimental Nephrology</i> , 2005, 101, e67-e74.	2.4	165
2	Klotho reduces apoptosis in experimental ischaemic acute renal failure. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2636-2645.	0.4	151
3	Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, F1252-F1264.	1.3	146
4	Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 60-68.	0.4	91
5	ATF3 Protects against Renal Ischemia-Reperfusion Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 217-224.	3.0	67
6	Effect of Single-Dose Rituximab on Primary Glomerular Diseases. <i>Nephron Clinical Practice</i> , 2011, 117, c98-c105.	2.3	54
7	Circulating levels of soluble $\hat{1}\pm$ -Klotho in patients with chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 795-796.	0.7	50
8	Risk Factors for Progression in Patients with Early-stage Chronic Kidney Disease in the Japanese Population. <i>Internal Medicine</i> , 2008, 47, 1859-1864.	0.3	39
9	The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. <i>Clinical and Experimental Nephrology</i> , 2007, 11, 214-217.	0.7	29
10	Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis. <i>Physiological Reports</i> , 2013, 1, e00172.	0.7	28
11	Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome. <i>Internal Medicine</i> , 2009, 48, 1901-1904.	0.3	27
12	Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2010, 14, 573-577.	0.7	23
13	Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model. <i>PLoS ONE</i> , 2018, 13, e0191706.	1.1	21
14	Recombinant Human Erythropoietin Mitigates Reductions in Renal Klotho Expression. <i>American Journal of Nephrology</i> , 2010, 32, 137-144.	1.4	20
15	Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. <i>International Urology and Nephrology</i> , 2012, 44, 841-845.	0.6	19
16	Ruptured Arterial Aneurysm of the Kidney in a Patient with Microscopic Polyangiitis. <i>Internal Medicine</i> , 2008, 47, 521-526.	0.3	15
17	Association between clinical characteristics and AL amyloid deposition in the kidney. <i>Heart and Vessels</i> , 2010, 25, 543-548.	0.5	10
18	Frequency of Renal Disease in Japan: An Analysis of 2,404 Renal Biopsies at a Single Center. <i>Nephron Clinical Practice</i> , 2010, 115, c227-c236.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Risedronate Therapy for the Prevention of Steroid-induced Osteoporosis in Patients with Minimal-change Nephrotic Syndrome. <i>Internal Medicine</i> , 2010, 49, 2065-2070.	0.3	7
20	CD2AP Expression in a Renal Ischemia/Reperfusion Injury Model and Analysis of Its Related Genes Using Overexpression and RNA Interference Technique. <i>American Journal of Nephrology</i> , 2005, 25, 373-381.	1.4	6
21	Three cases of late-onset oligomeganephronia. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 14-16.	1.4	6
22	Hyperammonemia with intermittent loss of consciousness caused by chronic portal-systemic shunt encephalopathy (CPSE) in hemodialysis patient-A case report. <i>Nihon Toseki Igakkai Zasshi</i> , 2007, 40, 445-450.	0.2	6
23	Pharmacokinetics of Orally Administered Tacrolimus in Lupus Nephritis Patients. <i>Yakugaku Zasshi</i> , 2010, 130, 113-118.	0.0	5
24	Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 893-899.	0.7	5
25	Combined IgG4 ⁺ and IgG1 ⁺ deposition in the glomerular and tubular basement membrane accompanied by autoimmune neutropenia (AIN) and immune thrombocytopenia (ITP). <i>CEN Case Reports</i> , 2015, 4, 206-211.	0.5	2
26	Three cases of abdominal angina in patients with chronic renal failure: successful treatment with prostaglandin E1. <i>Nihon Toseki Igakkai Zasshi</i> , 2004, 37, 329-334.	0.2	2
27	Anti-Glomerular Basement Membrane Antibody Disease with Granulomatous Lesions on Renal Biopsy. <i>Internal Medicine</i> , 2007, 46, 295-301.	0.3	1
28	Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome. <i>Case Reports in Nephrology</i> , 2019, 2019, 1-4.	0.2	1
29	6174ŽKlothoãè...Žæ€Šè²Šè;€ã«ã•ã•ã,Šã€ã;ã,ã•1¼Ÿ. <i>Nihon Toseki Igakkai Zasshi</i> , 2009, 42, 831-833.	0.2	1
30	A case of pulmonary dialysis-related amyloidosis with reticular opacity of the lung in a patient undergoing long-term dialysis. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 39-41.	1.4	0
31	A case report: The effect of Darubepoietin in a 64-year-old man on hemodialysis with pure red cell aplasia and adrenal dysfunction. <i>Nihon Toseki Igakkai Zasshi</i> , 2009, 42, 339-344.	0.2	0
32	Pulmonary embolism developing during thalidomide therapy for multiple myeloma in a hemodialysis patient. <i>Nihon Toseki Igakkai Zasshi</i> , 2011, 44, 951-956.	0.2	0